1 / 6

RED-HF Trial R eduction of E vents with D arbepoetin alfa in H eart F ailure Trial

RED-HF Trial R eduction of E vents with D arbepoetin alfa in H eart F ailure Trial. Duke Heart Failure Research Pager: 970-0736. Purpose.

nelly
Download Presentation

RED-HF Trial R eduction of E vents with D arbepoetin alfa in H eart F ailure Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RED-HF TrialReduction of Events with Darbepoetin alfa in Heart Failure Trial Duke Heart Failure Research Pager: 970-0736

  2. Purpose • Assess efficacy and safety of Darbepoetin alfa treatment on mortality and morbidity in heart failure subjects with symptomatic left ventricular systolic dysfunction and anemia Darbepoetin alfa – glycoprotein that stimulates erythropoietin, a hormone released from the kidney that develops red blood cells and produces hemoglobin

  3. Inclusion Criteria • EF ≤ 40% ● Hemoglobin ≥9 and ≤12 g/dL • HF ≥ 3 months & NYHA class II, III, or IV at randomization • ≥18 years old ● On stable medical therapy

  4. Interventions

  5. Nursing Roles • If an enrolled subject is admitted to the hospital, please notify the research team (970-0736) so that the study drug can be obtained and administrated at the appropriate time. • Side effects of Darbepoetin alfa (See Adverse Reactions List): http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=2571&sec=monadve

  6. Outcomes • Why is this study being done? • To compare the efficacy of Darbepoetin alfa to placebo as measured by the time to: • 1st hospital admission for worsening HF or • death

More Related